Methylglyoxal is a predictor in type 2 diabetic patients of intima-media thickening and elevation of blood pressure

Hypertension

Volumn 56, Issue 3, 2010, Pages 471-476

  Ogawa, Susumu ^a   Nakayama, Keisuke ^a   Nakayama, Masaaki ^a   Mori, Takefumi ^a   Matsushima, Masato ^b   Okamura, Masashi ^a   Senda, Miho ^a   Nako, Kazuhiro ^a   Miyata, Toshio ^a   Ito, Sadayoshi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

3 deoxyglucosone; diabetic macroangiopathy; hypertension; intima media thickness; methylglyoxal; pulse wave velocity

Indexed keywords

3 DEOXYGLUCOSONE; ALBUMIN; ALDOSTERONE ANTAGONIST; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; FIBRIC ACID DERIVATIVE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METHYLGLYOXAL; PIOGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; ARTERY INTIMA PROLIFERATION; ARTERY MEDIA; ARTICLE; BLOOD LEVEL; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DEPENDENT VARIABLE; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DISEASE DURATION; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INTIMA MEDIA THICKENING; LIQUID CHROMATOGRAPHY; MALE; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PULSE WAVE; QUANTITATIVE ANALYSIS; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; VASCULAR DISEASE;

BIOLOGICAL MARKERS; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPERTENSION; PROSPECTIVE STUDIES; PYRUVALDEHYDE; REGRESSION ANALYSIS; RISK FACTORS; TUNICA INTIMA; TUNICA MEDIA;

EID: 77955981191     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.156786     Document Type: Article

References (30)

1. Beisswenger PJ, Howell SK, Nelson RG, Mauer M, Szwergold BS. a-Oxoaldehyde metabolism and diabetic complications. Biochem Soc Trans. 2003;31:1358-1363.
2. Wu L. Is methylglyoxal a causative factor for hypertension development? Can J Physiol Pharmacol. 2006;84:129-139.
3. Chang T, Wu L. Methylglyoxal, oxidative stress, and hypertension. Can J Physiol Pharmacol. 2006;84:1229-1238.
4. Miyazawa N, Abe M, Souma T, Tanemoto M, Abe T, Nakayama M, Ito S. Methylglyoxal augments intracellular oxidative stress in human aortic endothelial cells. Free Radic Res. 2010;44:101-107.
5. Nakayama K, Nakayama M, Iwabuchi M, Terawaki H, Sato T, Kohno M, Ito S. Plasma a-oxoaldehyde levels in diabetic and nondiabetic chronic kidney disease patients. Am J Nephrol. 2008;28:871-878.
6. Beisswenger PJ, Drummond KS, Nelson RG, Howell SK, Szwergold BS, Mauer M. Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes. 2005;54:3274-3281.
7. Shinohara M, Thornalley PJ, Giardino I, Beisswenger P, Thorpe SR, Onorato J, Brownlee M. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest. 1998;101:1142-1147.
8. Guo Q, Mori T, Jiang Y, Hu C, Osaki Y, Yoneki Y, Sun Y, Hosoya T, Kawamata A, Ogawa S, Nakayama M, Miyata T, Ito S. Methylglyoxal contributes to the development of insulin resistance and salt sensitivity in Sprague-Dawley rats. J Hypertens. 2009;27:1664-1671.
9. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes. 1991;40:1328-1334.
10. Liu BF, Miyata S, Hirota Y, Higo S, Miyazaki H, Fukunaga M, Hamada Y, Ueyama S, Muramoto O, Uriuhara A, Kasuga M. Methylglyoxal induces apoptosis through activation of p38 mitogen-activated protein kinase in rat mesangial cells. Kidney Int. 2003;63:947-957.
11. Dhar A, Desai K, Kazachmov M, Yu P, Wu L. Methylglyoxal production in vascular smooth muscle cells from different metabolic precursors. Metabolism. 2008;57:1211-1220.
12. Odani H, Shinzato T, Matsumoto Y, Usami J, Maeda K. Increase in three a,/3-dicarbonyl compound levels in human uremic plasma: specific in vivo determination of intermediates in advanced Maillard reaction. Biochem Biophys Res Commun. 1999;256:89-93.
13. Han Y, Randell E, Vasdev S, Gill V, Curran M, Newhook LA, Grant M, Hagerty D, Schneider C. Plasma advanced glycation endproduct, methylglyoxal-derived hydroimidazolone is elevated in young, complication-free patients with type 1 diabetes. Clin Biochem. 2009;42: 562-569.
14. Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Hanssen KF, Laakso M. Increased serum levels of methylglyoxal-derived hydroimidazolone-AGE are associated with increased cardiovascular disease mortality in nondiabetic women. Atherosclerosis. 2009;205: 590-594.
15. Beisswenger PJ, Howell SK, O'Dell RM, Wood ME, Touchette AD, Szwergold BS. a-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care. 2001;24:726-732.
16. Ahmed N, Babaei-Jadidi R, Howell SK, Thornalley PJ, Beisswenger PJ. Glycated and oxidized protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes. Diabetes Care. 2005; 28:2465-2471.
17. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
18. Beisswenger PJ, Howell SK, Touchette AD, Lal S, Szwergold BS. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes. 1999;48:198-202.
19. Kiho T, Kato M, Usui S, Hirano K. Effect of buformin and metformin on formation of advanced glycation end products by methylglyoxal. Clin Chim Acta. 2005;358:139-145.
20. Yamada H, Miyata S, Igaki N, Yatabe H, Miyauchi Y, Ohara T, Sakai M, Shoda H, Oimomi M, Kasuga M. Increase in 3-deoxyglucosone levels in diabetic rat plasma. J Biol Chem. 1994;269:20275-20280.
21. Kusunoki H, Miyata S, Ohara T, Liu BF, Uriuhara A, Kojima H, Suzuki K, Miyazaki H, Yamashita Y, Inaba K, Kasuga M. Relation between serum 3-deoxyglucosone and development of diabetic microangiopathy. Diabetes Care. 2003;26:1889-1894.
22. El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper ME, Brownlee M. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med. 2008;29:205:2409-2417.
23. Nangaku M, Miyata T, Sada T, Mizuno M, Inagi R, Ueda Y, Ishikawa N, Yuzawa H, Koike H, Van Ypersele de Strihou C, Kurokawa K. Antihypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol. 2003;14:1212-1222.
24. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrell LA, Jerums G, Osicka TM. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes. 2002;51:3274-3282.
25. Mori T, Chen X, Hu C, Nakayama K, Nakamichi T, Hosoya T, Nagasawa T, Inoue H, Ogawa S, Nakayama M, Ito S. Methylglyoxal induced hypertension with angiotensin II mediated pathway in Dahl salt sensitive rats. J Hypertens. 2008;26:S524-S524.
26. Baden T, Yamawaki H, Saito K, Mukohda M, Okada M, Hara Y. Telmisartan inhibits methylglyoxal-mediated cell death in human vascular endothelium. Biochem Biophys Res Commun. 2008 22;373: 253-257.
27. Mori T, Chen X, Guo Q, Hu C, Ohsaki Y, Yoneki Y, Miyata T, Ito S. Carbonyl stress involvement in pathogenesis of cardiorenal connection in dahl salt-sensitive rats. Hypertension. 54:e86. Abstract.
28. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
29. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B, for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
30. Goh SY, Cooper ME. The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab. 2008;93:1143-1152.